ANTİ-TÜMÖR NEKROZİS FAKTÖR TEDAVİ VE KANSER

Soner Şenel; Saadettin Kılıçkap

Anti-tümör nekrozis faktör tedavisi ve kanser

Year 2010, Volume: 32 Issue: 1, 132 - 136, 11.03.2010

Soner Şenel , Saadettin Kılıçkap

Abstract

Özet

Anti-TNF antagonistleri birçok romatolojik hastalığın tedavisinde kullanılmaktadır. Bu grup ilaçların en önemli yan etkileri ciddi enfeksiyon ve ikincil kanser varlığı olarak bilinmektedir. Ancak anti-TNF tedavinin artmış kanser riski ile ilişkili olduğu konusundaki bilgiler net değildir. Bu makalede anti-TNF tedavi ve kanser arasındaki ilişkiden bahsedilmektedir.

Anahtar sözcükler: Anti-TNF tedavi, kanser, romatolojik hastalıklar.

Abstract

Anti-TNF antagonists are used in the treatment of several rheumatologic diseases. The most important side effects of these group drugs are known as serious infection and secondary malignancies. But, information about that anti-TNF therapy associates with the increased risk of cancer are unclear. In this article the relationship between anti-TNF therapy and cancer is mentioned.

Keywords: Anti-TNF therapy, cancer, rheumatological diseases.

Keywords

References

Oppenheim J, Feldmann M. Cytokine reference. San Diego: Academic Press; 2000.
Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995; 377: 348-51
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-8.
Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, Bast RC Jr. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 1993; 53: 1939-44.
Liu RY, Fan C, Liu G, Olashaw NE, Zuckerman KS. Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha supported proliferation of leukemia and lymphoma cell lines. J Biol Chem 2000; 275: 21086-93.
Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F. Mice deficient in tumor necrosis factor- alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828-31.
Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha- deficient mice. Cancer Res 1999; 59: 4516-8.
Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003;4:565-73.
Tsimberidou AM,Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res 2003; 27:375-80.
Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 1997; 15: 1052-62.
Nakashima C, Tanioka M, Takahashi K, Miyachi Y. Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate. Clinical and Experimental Dermatology, 2008; 33: 437-9.
Cansu DU, Kasifoglu T, Acıkalın M, Korkmaz C. The Development of Primary Cutaneous Adenoid Cystic Carcinoma in a Patient with Ankylosing Spondylitis Treated with Etanercept. South Med J 2009; 102 : 738-40.
Aksu K, Donmez A, Ertan Y, Keser G, Inal V, Oder G, Tombuloglu M, Kabasakal Y, Doganavsargil E. Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitis Rheumatol Int 2007;28:185-7.
Simsek I, Pay S, Dinc A, Erdem H, Kurt B. Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment-case report. Clin Rheumatol 2007; 26:1561-2.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004; 50:1740-51.
Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and U.S. postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 65: 889-94.
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis.N Engl J Med. 2000;343: 1594-602.
Bathon JM, Martin RW, Fleischmann RM,Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000; 343: 1586-93.
Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L, Cochrane CJ, Aitken S, Fennell J, Rogers P, Shand AG, Penman ID, Palmer KR, Wilson DC, Arnott ID, Satsangi J. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009; 29: 286-97.
Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää- Dahlqvist S, Saxne T, Klareskog L. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapies: Does the risk change with the time since start of treatment. Arthritis Rheum 2009; 60: 3180-9.
Askling J, Fored C M, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson L T, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L. Risks of solid cancers in patients with rheumatoid arthritis and following treatment with TNF-antagonists. Ann Rheum Dis 2005; 64: 1421-6.
Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2757-64.
Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-95.
Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT. TNF blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703.
Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzani C, Gorla R, Marchesoni A, Favalli EG, Montecucco C. Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry. Autoimmun Rev. 2010;9 :175-80.